PDGFRB and cholangiocarcinoma: While multitarget kinase inhibitors like imatinib and sunitinib have shown promise in disrupting PDGFR signaling, they can inhibit CCA cell proliferation, migration, and invasion [20] and sensitize CCA cells to TRAIL-induced apoptosis [21].